glp-1 agonist drug interactions Comparing Ozempic, Wegovy and Other Drugs Exploring the Side Effects of

Understanding which patients are candidates for GLP-1RAs treatment will be key, according to Lorenzo Leggio, MD, PhD, clinical director of the National Institute on Drug Abuse

In the SURPASS 2 trial, Tirzepatide at all doses (5mg, 10mg and 15mg) was found to result in greater weight loss than semaglutide 1mg

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

GLP-1-based therapies for diabetes, obesity and beyond

Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor

Another novel glucose-lowering agent is tirzepatide which has a dual mechanism of action: a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) co-agonist